Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topotecan With or Without Ziv-aflibercept in Platinum-Treated Extensive Stage SCLC
NCT00828139Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2009
- Primary completion
- Sep 2012
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of aflibercept in small cell lung cancer (SCLC), sponsored by National Cancer Institute. Started May 2009; status: completed.
02
Drugs
aflibercept
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00828139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00828139.